Synthon Hispania

Synthon Hispania is a prominent pharmaceutical company based in Sant Boi de Llobregat, Spain, serving as a core R&D and manufacturing hub for the global Synthon group. The company specializes in the development and production of complex generic medicines, particularly in the fields of oncology and neurology. Its state-of-the-art facilities are equipped to handle high-potency active pharmaceutical ingredients (HPAPIs) and complex oral solid dosage forms. Synthon Hispania is well-known for its successful development of generic glatiramer acetate, a complex peptide used in the treatment of multiple sclerosis. Following the acquisition of the Synthon group by BC Partners in 2019, the company has continued to expand its portfolio of value-added medicines. It provides comprehensive services ranging from early-stage chemical research to large-scale commercial manufacturing for global markets.